Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study.
Assoumou L, Baldé R, Katlama C, Abbar B, Delobel P, Allegre T, Lavole A, Makinson A, Zaegel-Faucher O, Greillier L, Soulie C, Veyri M, Bertheau M, Algarte Genin M, Gibowski S, Marcelin AG, Bihan K, Baron M, Costagliola D, Lambotte O, Spano JP.
Assoumou L, et al. Among authors: marcelin ag.
J Immunother Cancer. 2024 Aug 22;12(8):e009728. doi: 10.1136/jitc-2024-009728.
J Immunother Cancer. 2024.
PMID: 39179255
Free PMC article.